ArticleJournal of clinical laboratory analysis2022
LINC00240 knockdown inhibits nasopharyngeal carcinoma progress by targeting miR-26a-5p.
Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Expression and Regulatory Mechanisms of MicroRNA in Cholesteatoma: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- LINC00240 Knockdown Suppresses the Proliferation, Migration, and Invasion of Ovarian Cancer Cells Through the miR-30c-5p/P4HA2 Axis.Journal of cellular and molecular medicine · 2026Article
- The Role of lncRNA-miR-26a-mRNA Network in Cancer Progression and Treatment.Biochemical genetics · 2024Review
- Role of LINC00240 on T-helper 9 differentiation in allergic rhinitis through influencing DNMT1-dependent methylation of PU.1.Immunologic research · 2024Article
- Angiogenesis in nasopharyngeal carcinoma: insights, imaging, and therapeutic strategies.Frontiers in oncology · 2024Review
- Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance.Journal of translational medicine · 2023Review
- LINC00240 knockdown inhibits nasopharyngeal carcinoma progress by targeting miR-26a-5p.Journal of clinical laboratory analysis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThis study intended to explore the regulatory functions of LINC00240 on nasopharyngeal carcinoma (NPC).
methodsMiR-26a-5p inhibitor, mimic, and siLINC00240 were transfected into NPC cells. QRT-PCR was employed to assess miR-26a-5p and LINC00240 expressions. The targeting relationship of LINC00240 and miR-26a-5p was analyzed through dual luciferase reporter and RNA immunoprecipitation assay. Cell counting kit-8 assay, colony formation assay, flow cytometry assay, wound healing assay, Transwell assay and in vitro angiogenesis assay were adopted for the evaluation of the effects of LINC00240 or miR-26a-5p and LINC00240 on NPC cells regarding cell proliferation, apoptosis and cycle, migration, invasion, and angiogenesis. EZH2, cell cycle, and epithelial-mesenchymal transition (EMT)-related protein expression was tested through Western blot.
resultsLINC00240 had a high expression in NPC tissues and cell lines. Silenced LINC00240 significantly suppressed the 5-8F and HK1 cell proliferation, invasion, migration, and angiogenesis, but raised cell apoptosis, and cells were blocked in G0/G1 phase. MiR-26a-5p was a target of LINC00240. MiR-26a-5p upregulation suppressed the NPC cell proliferation, migration, invasion, angiogenesis, N-cadherin and EZH2 expression, while it elevated apoptosis and p21, p27 and E-cadherin expressions, whereas miR-26a-5p downregulation performed conversely. LINC00240 knockdown partially offset the effects of miR-26a-5p downregulation on cell proliferation, migration, invasion, angiogenesis, apoptosis, and EZH2.
conclusionLINC00240 knockdown restrained cell proliferation, invasion, migration, and angiogenesis, while it advanced apoptosis via miR-26a-5p in NPC by EZH2 inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.